Alzheimer’s disease drug development pipeline: 2021

Cited by (535)

Items 101–200 of 535

1. AI-DrugNet: A network-based deep learning model for drug repurposing and combination therapy in neurological disorders
   Xingxin Pan, Jun Yun, Zeynep Coban‐Akdemir, Xiaoqian Jiang, Erxi Wu, Jason Haitao Huang, Nidhi Sahni, S. Stephen Yi · 2023 · Computational and Structural Biotechnology Journal
2. The Vascular-Immune Hypothesis of Alzheimer’s Disease
   Rashi I. Mehta, Rupal I. Mehta · 2023 · Biomedicines
3. A call for clinical trial globalization in Alzheimer's disease and related dementia
   Llibre‐Guerra, Jorge J., Heavener, Anika, Brucki, Sonia Maria Dozzi, Marante, Juan Pablo Díaz, Pintado‐Caipa, Maritza, Chen, Yaohua, Behrens, María Isabel, Hardi, Angela, Admirall‐Sanchez, Arianna, Akinyemi, Rufus et al. · 2023 · Alzheimer's & Dementia
4. A Path to Improved Alzheimer’s Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer’s Disease from the CLARITY AD Trial
   Amir Abbas Tahami Monfared, Weicheng Ye, Aditya Sardesai, Henri Folse, Ameya Chavan, Elena Aruffo, Quanwu Zhang · 2023 · Neurology and Therapy
5. Unraveling Alzheimer’s: the promise of aducanumab, lecanemab, and donanemab
   Taha Basit Ameen, Syeda Naveera Kashif, Syed Muhammad Iraj Abbas, Kulsoom Babar, Syed Muhammad Sinaan Ali, Abdul Raheem · 2024 · The Egyptian Journal of Neurology Psychiatry and Neurosurgery
6. Exploring easily accessible neurophysiological biomarkers for predicting Alzheimer’s disease progression: a systematic review
   Matteo Costanzo, Carolina Cutrona, Giorgio Leodori, Leonardo Malimpensa, Fabrizia D’Antonio, Antonella Conte, Daniele Belvisi · 2024 · Alzheimer s Research & Therapy
7. From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics
   Akash Roy, Valina Lynn Dawson, Ted M. Dawson · 2025 · Neurotherapeutics
8. Temperature-Dependent Structural Variability of Prion Protein Amyloid Fibrils
   Mantas Žiaunys, Andrius Sakalauskas, Kamilė Mikalauskaitė, Rūta Sniečkutė, Vytautas Smirnovas · 2021 · International Journal of Molecular Sciences
9. Evaluation of the Cost-effectiveness of Drug Treatment for Alzheimer Disease in a Simulation Model That Includes Caregiver and Societal Factors
   Kouta Ito, Rick Chapman, Steven D. Pearson, Ali Tafazzoli, Kristine S. Yaffe, Jerry H. Gurwitz · 2021 · JAMA Network Open
10. Mitochondrial Membrane Potential Influences Amyloid-β Protein Precursor Localization and Amyloid-β Secretion
    Heather Wilkins, Benjamin Troutwine, Blaise W. Menta, Sharon Manley, Taylor Strope, Colton Lysaker, Russell Swerdlow · 2021 · Journal of Alzheimer s Disease
11. Calcium Signaling Regulated by Cellular Membrane Systems and Calcium Homeostasis Perturbed in Alzheimer’s Disease
    Dongxu Huang, Xin Yu, Wen-Jun Yu, Xinmin Zhang, Chang Liu, Hongping Liu, Yue Sun, Ziping Jiang · 2022 · Frontiers in Cell and Developmental Biology
12. Eye movement changes as an indicator of mild cognitive impairment
    Julius Opwonya, Boncho Uk Ku, Kun Ho Lee, Joong Il Kim, Jaeuk U. Kim · 2023 · Frontiers in Neuroscience
13. Tau Seeding Mouse Models with Patient Brain-Derived Aggregates
    Aiko Robert, Michael Schöll, Thomas Vogels · 2021 · International Journal of Molecular Sciences
14. Design, synthesis and evaluation of quinoline- O -carbamate derivatives as multifunctional agents for the treatment of Alzheimer’s disease
    Hongsong Chen, Jing Mi, Sen Li, Zhengwei Liu, Jing Liang Yang, Rui Chen, Yujie Wang, Yujuan Ban, Yi Ming Zhou, Wu Dong et al. · 2023 · Journal of Enzyme Inhibition and Medicinal Chemistry
15. Targeting epigenetics: A novel promise for Alzheimer’s disease treatment
    Danko Jeremic, Lydia Jiménez‐Díaz, Juan D. Navarro‐López · 2023 · Ageing Research Reviews
16. Lipid Homeostasis and Its Links With Protein Misfolding Diseases
    Michele Vendruscolo · 2022 · Frontiers in Molecular Neuroscience
17. Urolithin A exhibits a neuroprotective effect against Alzheimer’s disease by inhibiting DYRK1A activity
    Huang‐Ju Tu, C SU, Chao-Shiang Peng, Tony Eight Lin, Wei-Chun Huang Fu, Kai‐Cheng Hsu, Tsong‐Long Hwang, Shiow‐Lin Pan · 2023 · Journal of Food and Drug Analysis
18. Role of Lipocalin-2 in Amyloid-Beta Oligomer-Induced Mouse Model of Alzheimer’s Disease
    Heeyoung Kang, Hyun Joo Shin, Hyeong Seok An, Zhen Hua Jin, Jong Youl Lee, Jaewoong Lee, Kyung Eun Kim, Eun Ae Jeong, Kyu Yeong Choi, Catriona McLean et al. · 2021 · Antioxidants
19. Protein and Gene Delivery Systems for Neurodegenerative Disorders: Where Do We Stand Today?
    Panoraia I. Siafaka, Mehmet Evren Okur, Pelin Dilsiz, Emre Şefik Çağlar, Emre Özgenç, Evren Gündoğdu, Rabia Edibe Parlar Köprülü, Ioannis D. Karantas, Neslihan Üstündağ Okur · 2022 · Pharmaceutics
20. Co‐Assembled Nanoparticles toward Multi‐Target Combinational Therapy of Alzheimer's Disease by Making Full Use of Molecular Recognition and Self‐Assembly
    Wen‐Bo Li, Linlin Xu, Si‐Lei Wang, Ying‐Yue Wang, Yu‐Chen Pan, Linqi Shi, Dong‐Sheng Guo · 2024 · Advanced Materials
21. Tau protein aggregation: Key features to improve drug discovery screening
    Johanna Giovannini, Willy Smeralda, Marie Jouanne, Jana Sopková‐de Oliveira Santos, Marco Catto, Anne Sophie Voisin‐Chiret · 2022 · Drug Discovery Today
22. Opportunities and challenges in delivering biologics for Alzheimer’s disease by low-intensity ultrasound
    Liyu Chen, Esteban Cruz, Lotta E. Oikari, Pranesh Padmanabhan, Jae Hee Song, Jürgen Götz · 2022 · Advanced Drug Delivery Reviews
23. The Potential of Small Molecules to Modulate the Mitochondria–Endoplasmic Reticulum Interplay in Alzheimer’s Disease
    Giacomo Dentoni, Laura Castro‐Aldrete, Luana Naia, Maria Ankarcrona · 2022 · Frontiers in Cell and Developmental Biology
24. Probing neural circuit mechanisms in Alzheimer’s disease using novel technologies
    Steven F. Grieco, Todd C. Holmes, Xiangmin Xu · 2023 · Molecular Psychiatry
25. Comparison of the telephone‐Montreal Cognitive Assessment (T‐MoCA) and Telephone Interview for Cognitive Status (TICS) as screening tests for early Alzheimer's disease
    Sheridan D. Chappelle, Christina M. Gigliotti, Gabriel C. Léger, Guerry M. Peavy, Diane M. Jacobs, Sarah Jane Banks, Emily A. Little, Douglas R Galasko, David P. Salmon · 2023 · Alzheimer s & Dementia
26. Dissecting Detergent-Insoluble Proteome in Alzheimer's Disease by TMTc-Corrected Quantitative Mass Spectrometry
    Masihuz Zaman, Yingxue Fu, Ping‐Chung Chen, Huan Sun, Shu Yang, Zhiping Wu, Zhen Wang, Suresh Poudel, Geidy E. Serrano, Thomas G. Beach et al. · 2023 · Molecular & Cellular Proteomics
27. The Therapeutic and Diagnostic Potential of Amyloid β Oligomers Selective Antibodies to Treat Alzheimer’s Disease
    Kirsten L. Viola, Maira Assunção Bicca, Adrian M. Bebenek, Daniel L. Kranz, Vikas Nandwana, Emily Alexandria Waters, Chad R. Haney, Maxwell Y Lee, Abhay Gupta, Zachary Brahmbhatt et al. · 2022 · Frontiers in Neuroscience
28. Association of Plasma YKL-40 With MRI, CSF, and Cognitive Markers of Brain Health and Dementia
    Matthew Paul Pase, Jayandra Jung Himali, Raquel Puerta, Alexa Beiser, Mitzi M. Gonzales, Claudia Liliana Satizábal, Qiong Yang, Hugo Javier Aparicio, Daniel J. Kojis, Charles S DeCarli et al. · 2024 · Neurology
29. Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer’s disease assessment
    Darren M. Weber, Steven W. Taylor, ROBERT J. LAGIER, Jueun C Kim, Scott M. Goldman, Nigel J. Clarke, David E. Vaillancourt, Ranjan Duara, Karen N. McFarland, Wei‐en Wang et al. · 2024 · Frontiers in Neurology
30. SNAP-25: A biomarker of synaptic loss in neurodegeneration
    Chaoqun Zhang, Shanshan Xie, Melika Malek · 2025 · Clinica Chimica Acta
31. Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease
    Ellen Y. Cotrina, Luís Miguel Santos, Josep Rivas, Daniel Blasi, José P. Leite, Márcia A. Liz, Maria Antònia Busquets, Antoni Planas, Rafel Prohens, Ana Gimeno et al. · 2021 · European Journal of Medicinal Chemistry
32. Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia
    Ruiqing Ni, Roger M. Nitsch · 2022 · Frontiers in Aging Neuroscience
33. Repopulated microglia induce expression of Cxcl13 with differential changes in Tau phosphorylation but do not impact amyloid pathology
    Berke Karaahmet, Linh Le, Monique S. Mendes, Ania Katarzyna Majewska, M. Kerry O’Banion · 2022 · Journal of Neuroinflammation
34. Asthma amplifies dementia risk: Evidence from CSF biomarkers and cognitive decline
    Ajay Kumar Nair, Carol Ann Van Hulle, Barbara B. Bendlin, Henrik Zetterberg, Kaj Blennow, Norbert Wild, Gwendlyn Kollmorgen, Ivonne Suridjan, William W. Busse, Melissa A. Rosenkranz · 2022 · Alzheimer s & Dementia Translational Research & Clinical Interventions
35. Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials
    Pâmela C.L. Ferreira, João Pedro Ferrari‐Souza, Cécile Tissot, Bruna Bellaver, Douglas Teixeira Leffa, Firoza Zubeida Lussier, Guilherme Povala, Joseph Therriault, Andréa Lessa Benedet, Nicholas James Ashton et al. · 2023 · Neurology
36. Cognitive and Functional Change Over Time in Cognitively Healthy Individuals According to Alzheimer Disease Biomarker-Defined Subgroups
    Mark A. Dubbelman, Heleen M. A. Hendriksen, John Harrison, Everard G.B. Vijverberg, Niels D. Prins, Lior A. Kroeze, Lois Ottenhoff, Mardou S. S. A. van Leeuwenstijn, Inge M.W. Verberk, Charlotte Elisabeth Teunissen et al. · 2023 · Neurology
37. Navigating the dementia landscape: Biomarkers and emerging therapies
    Shubhrat Maheshwari, Aditya Singh, Valeed Ahmad Ansari, Tarique Mahmood, Rufaida Wasim, Juber Akhtar, Amita Verma · 2024 · Ageing Research Reviews
38. Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough
    Rishabh Rishabh, Manni Rohilla, Seema Bansal, Nitin Bansal, Samrat Chauhan, Sheenam Sharma, Navjyoti Goyal, Sumeet Gupta · 2024 · European Journal of Neuroscience
39. An insight into prodrug strategy for the treatment of Alzheimer’s disease
    Neha V. Bhilare, Vinayak S. Marulkar, Dileep Kumar, Vivekanand Kisan Chatap, Kashmira S. Patil, Pramodkumar J. Shirote · 2022 · Medicinal Chemistry Research
40. Alzheimer's disease amyloid-β pathology in the lens of the eye
    Juliet A. Moncaster, Robert D. Moir, Mark A. Burton, Oliver Chadwick, Olga V. Minaeva, Victor E. Alvarez, Maria Ericsson, John I. Clark, Ann Carolyn McKee, Rudolph E. Tanzi et al. · 2022 · Experimental Eye Research
41. Could drugs prevent Alzheimer’s? These trials aim to find out
    Alison Abbott · 2022 · Nature
42. Beyond the amyloid cascade: An update of Alzheimer's disease pathophysiology
    Dominique Gouilly, Marie Rafiq, Léonor Nogueira, Anne‐Sophie Salabert, Pierre Payoux, Patrice Péran, Jérémie Pariente · 2023 · Revue Neurologique
43. Cognitive impairment in individuals with rheumatic diseases: the role of systemic inflammation, immunomodulatory medications, and comorbidities
    Elena Myasoedova, Sebastian Eduardo Sattui, Jihae Lee, John Tiernan O'Brien, Una E. Makris · 2024 · The Lancet Rheumatology
44. Therapeutic modulation of neurogenesis to improve hippocampal plasticity and cognition in aging and Alzheimer's disease
    MOSTAFA MOSTAFA, Ahmed Disouky, Orly Lazarov · 2025 · Neurotherapeutics
45. Pharmacological Strategies to Improve Dendritic Spines in Alzheimer’s Disease
    Miren Ettcheto, Oriol Busquets, Amanda C. Cano, Elena Sánchez‐López, Patrícia Regina Manzine, Triana Espinosa-Jiménez, Ester Verdaguer, Francesc Xavier Sureda, Jordi Olloquequi, Ruben Dario Castro-Torres et al. · 2020 · Journal of Alzheimer s Disease
46. Discovery of carbamate-based N-salicyloyl tryptamine derivatives as novel pleiotropic agents for the treatment of Alzheimer's disease
    Yuying Wang, Honghua Zhang, Dan Liu, Xuelin Li, Lin Long, Ying Peng, Fujian Qi, Yuqing Wang, Weifan Jiang, Zhen Wang · 2022 · Bioorganic Chemistry
47. The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report
    Julien Delrieu, Randall John Bateman, Jacques Touchon, Marwan Sabbagh, Jeffrey L. Cummings · 2022 · The Journal of Prevention of Alzheimer s Disease
48. Metal–Organic Framework-Derived Carbon as a Photoacoustic Modulator of Alzheimer’s β-Amyloid Aggregate Structure
    Jinhyeong Jang, Yonghan Jo, Chan Beum Park · 2022 · ACS Nano
49. Decoding the Roles of Amyloid-β (1–42)’s Key Oligomerization Domains toward Designing Epitope-Specific Aggregation Inhibitors
    Dongjoon Im, Soohyeong Kim, Gyusub Yoon, Da Gyeong Hyun, Yu‐Gon Eom, Ye Eun Lee, Chang Ho Sohn, Jeong‐Mo Choi, Hugh I. Kim · 2023 · JACS Au
50. Design, synthesis and bioevaluation of 1,2,4-thiadiazolidine-3,5-dione derivatives as potential GSK-3β inhibitors for the treatment of Alzheimer's disease
    Dong, Yongxi, Lu, Jun, Zhang, Shanhui, Chen, Lina, Wen, Jinlan, Wang, Fang, Mao, Yongqing, Li, Lei, Zhang, Jiquan, Liao, Shanggao et al. · 2023 · Bioorganic Chemistry
51. Amyloid-β mediates intestinal dysfunction and enteric neurons loss in Alzheimer's disease transgenic mouse
    Guoqiang Liu, Quntao Yu, Houze Zhu, Bo Tan, Hongyan Yu, Xinyan Li, Youming Lu, Hao Li · 2023 · Cellular and Molecular Life Sciences
52. Greater Diffusion Restriction in White Matter in Preclinical Alzheimer Disease
    Andreana M. Benitez, Jens H. Jensen, Kathryn E. Thorn, Siddhartha Dhiman, Stephanie Fountain‐Zaragoza, William J. Rieter, Maria Vittoria Spampinato, Eric Daniel Hamlett, Paul J. Nietert, Maria Fatima Falangola et al. · 2022 · Annals of Neurology
53. Lysozyme Amyloid Fibril Structural Variability Dependence on Initial Protein Folding State
    Kamilė Mikalauskaitė, Mantas Žiaunys, Vytautas Smirnovas · 2022 · International Journal of Molecular Sciences
54. The Landscape of m6A Regulators in Multiple Brain Regions of Alzheimer’s Disease
    ZiJie Liu, Qing Hua Xia, Xue Ling Zhao, Feifei Zheng, Jiaying Xiao, Fangliang Ge, Dayong Wang, Xu Gao · 2023 · Molecular Neurobiology
55. Probing gut‐brain links in Alzheimer's disease with rifaximin
    Paul V. Suhocki, James Ronald, Anna Mae Diehl, David M. Murdoch, Pudugramam Murali Doraiswamy · 2022 · Alzheimer s & Dementia Translational Research & Clinical Interventions
56. Reversal of Lipid Metabolism Dysregulation by Selenium and Folic Acid Co-Supplementation to Mitigate Pathology in Alzheimer’s Disease
    Zhonghao Zhang, Xian-Chun Cao, Jiaying Peng, Shaoling L. Huang, Chen Chen, Shi-Zheng Jia, Jiazuan Ni, Guo-Li Song · 2022 · Antioxidants
57. Preventive Effect of Betaine Against Cognitive Impairments in Amyloid β Peptide-Injected Mice Through Sirtuin1 in Hippocampus
    Daisuke Ibi, Sari Kondo, Ayano Ohmi, Yuya Kojima, Genki Nakasai, Rika Takaba, Masayuki Hiramatsu · 2022 · Neurochemical Research
58. Determining the Minimal Important Change of Everyday Functioning in Dementia
    Mark A. Dubbelman, Merike Verrijp, Caroline Barbara Terwee, Roos J. Jutten, Merel C. Postema, Frederik Barkhof, Bart N.M. van Berckel, Freek Gillissen, Vivianne Teeuwen, Charlotte Elisabeth Teunissen et al. · 2022 · Neurology
59. The elusive role of herpesviruses in Alzheimer’s disease: current evidence and future directions
    Stacey L. Piotrowski, Allison Tucker, Steven Jacobson · 2023 · NeuroImmune Pharmacology and Therapeutics
60. Natural Products from Plants and Algae for Treatment of Alzheimer’s Disease: A Review
    Klose, Jana, Griehl, Carola, Roßner, Steffen, Schilling, Stephan · 2022 · Biomolecules
61. Neuronanomedicine for Alzheimer’s and Parkinson’s disease: Current progress and a guide to improve clinical translation
    India Boyton, Stella M. Valenzuela, Lyndsey E. Collins‐Praino, Andrew Care · 2023 · Brain Behavior and Immunity
62. Stimulating myelin restoration with BDNF: a promising therapeutic approach for Alzheimer's disease
    Ioanna Zota, Konstantina Chanoumidou, Achille Gravanis, Ioannis Charalampopoulos · 2024 · Frontiers in Cellular Neuroscience
63. Polyphenols and Alzheimer's Disease: A Review on Molecular and Therapeutic Insights With In Silico Support
    Guifei Chen, Yan A. Su, Siyu Chen, Tiandong Lin, Xueying Lin · 2025 · Food Science & Nutrition
64. Multiparametric hippocampal signatures for early diagnosis of Alzheimer's disease using 18 F‐FDG PET / MRI Radiomics
    Zhigeng Chen, Sheng Bi, Yi Shan, Bixiao Cui, Hongwei Yang, Zhigang Qi, Zhilian Zhao, Ying Han, Shaozhen Yan, Jie Lu · 2023 · CNS Neuroscience & Therapeutics
65. Epigenetic Explorations of Neurological Disorders, the Identification Methods, and Therapeutic Avenues
    Zeba Firdaus, Xiaogang Li · 2024 · International Journal of Molecular Sciences
66. Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders
    Maurits F. J. M. Vissers, Jules A. A. C. Heuberger, Geert Jan Groeneveld · 2021 · International Journal of Molecular Sciences
67. Mitochondrial defects: An emerging theranostic avenue towards Alzheimer's associated dysregulations
    Shalini Mani, Geeta Swargiary, Manisha Singh, Shriya Agarwal, Abhijit Dey, Shreesh Kumar Ojha, Niraj Kumar Jha · 2021 · Life Sciences
68. Novel S1R agonists counteracting NMDA excitotoxicity and oxidative stress: A step forward in the discovery of neuroprotective agents
    Pasquale Linciano, Claudia Sorbi, Giacomo Rossino, Daniela Rossi, Andrea Marsala, Nunzio Denora, Martina Bedeschi, Noemi Marino, Giacomo Miserocchi, Giulio Massimo Dondio et al. · 2023 · European Journal of Medicinal Chemistry
69. Mayo‐PACC: A parsimonious preclinical Alzheimer's disease cognitive composite comprised of public‐domain measures to facilitate clinical translation
    Nikki H. Stricker, Erin L. Twohy, Sabrina M. Albertson, Aimee James Karstens, Walter K. Kremers, Mary M. Machulda, Julie A. Fields, Clifford R. Jack, David S. Knopman, Michelle M. Mielke et al. · 2022 · Alzheimer s & Dementia
70. Promising protein biomarkers in the early diagnosis of Alzheimer’s disease
    Lalit Kumar Sharma, Aditi Sharma, Deepak Kumar, Manish Kumar Asthana, H. Lalhlenmawia, Ashwani Kumar, Sanjib Bhattacharyya, Deepak Kumar · 2022 · Metabolic Brain Disease
71. Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
    Wiesje Pelkmans, Eleonora M. Vromen, Ellen Dicks, Philip Scheltens, Charlotte Elisabeth Teunissen, Frederik Barkhof, Wiesje M. van der Flier, Betty Marije Tijms, Alzheimer’s Disease Neuroimaging Initiative · 2022 · Brain Communications
72. The Major Hypotheses of Alzheimer’s Disease: Related Nanotechnology-Based Approaches for Its Diagnosis and Treatment
    César Cáceres, Bernardita Heusser, Alexandra Garnham, Ewa Moczko · 2023 · Cells
73. Early detection and personalized medicine: Future strategies against Alzheimer's disease
    Antonio Di Meco, Robert J. Vassar · 2020 · Progress in molecular biology and translational science
74. The Implication of STEP in Synaptic Plasticity and Cognitive Impairments in Alzheimer’s Disease and Other Neurological Disorders
    Yacoubou Abdoul Razak Mahaman, Fang Huang, Kidane Siele Embaye, Xiaochuan Wang, Feiqi Zhu · 2021 · Frontiers in Cell and Developmental Biology
75. The involvement of SigmaR1K142 degradation mediated by ERAD in neural senescence linked with CdCl2 exposure
    Bo Qian, Tingyu Li, Zhao-Xuan Zheng, Hanyu Zhang, Wenqi Xu, Su-Min Mo, Jiajia Cui, Wei-Jie Chen, Yu‐Chun Lin, Zhong‐Ning Lin · 2024 · Journal of Hazardous Materials
76. Does resistance training in older adults lead to structural brain changes associated with a lower risk of Alzheimer’s dementia? A narrative review
    Louisa Nicola, Stephanie Jyet Quan Loo, Gabrielle Lyon, Josh Turknett, Thomas R. Wood · 2024 · Ageing Research Reviews
77. Ceanothanes Derivatives as Peripheric Anionic Site and Catalytic Active Site Inhibitors of Acetylcholinesterase: Insights for Future Drug Design
    Sofía Pastene-Burgos, Evelyn Muñoz, Soledad Quiroz‐Carreño · 2024 · International Journal of Molecular Sciences
78. Targeting the epigenome to treat neurodegenerative diseases or delay their onset: a perspective
    Fabio Coppedè · 2021 · Neural Regeneration Research
79. Two new alkaloids from Dendrobium nobile Lindl. exhibited neuroprotective activity, and dendrobine alleviated Aβ1−42‐induced apoptosis by inhibiting CDK5 activation in PC12 cells
    Cheng‐Chen Zhang, Yan‐Li Kong, Mao‐Sheng Zhang, Qin Wu, Shi Jing-shan · 2023 · Drug Development Research
80. Estimating Transition Probabilities Across the Alzheimer’s Disease Continuum Using a Nationally Representative Real-World Database in the United States
    Amir Abbas Tahami Monfared, Shuai Fu, Noemi Hummel, Luyuan Qi, Aastha N. Chandak, Raymond J. Zhang, Quanwu Zhang · 2023 · Neurology and Therapy
81. Alzheimer’s disease is an inherent, natural part of human brain aging: an integrated perspective
    Isidró Ferrer · 2022 · Free Neuropathology
82. Alzheimer’s disease prediction algorithm based on de-correlation constraint and multi-modal feature interaction
    Jiayuan Cheng, Huabin Wang, Shicheng Wei, Jiahao Mei, Fei Liu, Gong Zhang · 2024 · Computers in Biology and Medicine
83. A comprehensive review of advanced focused ultrasound (FUS) microbubbles-mediated treatment of Alzheimer’s disease
    Rouhi, Nadiyeh, Chakeri, Zahra, Ghorbani Nejad, Behnam, Rahimzadegan, Milad, Rafi Khezri, Mohammad, Kamali, Hossein, Nosrati, Rahim · 2024 · Heliyon
84. (-)-Oleocanthal Nutraceuticals for Alzheimer’s Disease Amyloid Pathology: Novel Oral Formulations, Therapeutic, and Molecular Insights in 5xFAD Transgenic Mice Model
    Afsana Tajmim, Areli K. Cuevas-Ocampo, Abu Bakar Siddique, Mohammed H. Qusa, Judy Ann King, Khaldoun S. Abdelwahed, Jafrin Jobayer Sonju, Khalid A. El Sayed · 2021 · Nutrients
85. Carnosic Acid Attenuates AβOs-Induced Apoptosis and Synaptic Impairment via Regulating NMDAR2B and Its Downstream Cascades in SH-SY5Y Cells
    Wenying Liu, Yan Li, Yan Li, Lingzhi Xu, Jianping Jia · 2022 · Molecular Neurobiology
86. Gut Microbiota and Immunotherapy for Alzheimer’s Disease
    Chun‐Ling Dai, Fei Liu, Khalid Iqbal, Cheng‐Xin Gong · 2022 · International Journal of Molecular Sciences
87. Cardiorespiratory fitness and risk of Alzheimer's disease and related dementias among American veterans
    Yan Cheng, EDWARD Y. ZAMRINI, Charles J. Faselis, Douglas Redd, Yijun Shao, Charity Johanna Morgan, Helen M. Sheriff, Ali Ahmed, Peter F Kokkinos, Qing Zeng‐Treitler · 2023 · Alzheimer s & Dementia
88. Stricker Learning Span criterion validity: a remote self-administered multi-device compatible digital word list memory measure shows similar ability to differentiate amyloid and tau PET-defined biomarker groups as in-person Auditory Verbal Learning Test
    Nikki H. Stricker, John L. Stricker, Ryan D. Frank, Winnie Z. Fan, Teresa J. H. Christianson, Jay S. Patel, Aimee James Karstens, Walter K. Kremers, Mary M. Machulda, Julie A. Fields et al. · 2023 · Journal of the International Neuropsychological Society
89. Association of Blood MicroRNA Expression and Polymorphisms with Cognitive and Biomarker Changes in Older Adults
    Angélique Sadlon, Petros Takousis, Εvangelos Εvangelou, Inga Prokopenko, Panagiotis Alexopoulos, Chinedu Theresa Udeh‐Momoh, Geraint J. Price, Lefkos T. Middleton, Robert Perneczky · 2023 · The Journal of Prevention of Alzheimer s Disease
90. P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles
    Kirsten E. J. Wesenhagen, Betty Marije Tijms, Lynn Boonkamp, Patty L. Hoede, Julie Goossens, Nele Dewit, Philip Scheltens, Eugeen Vanmechelen, Pieter Jelle Visser, Charlotte Elisabeth Teunissen · 2022 · Alzheimer s Research & Therapy
91. Relationship between adult subventricular neurogenesis and Alzheimer’s disease: Pathologic roles and therapeutic implications
    Hyeon Soo Kim, Seong Min Shin, Sujin Kim, Yunkwon Nam, Anji Yoo, M. Moon · 2022 · Frontiers in Aging Neuroscience
92. A Bibliometric and Visual Analysis of Exercise Intervention Publications for Alzheimer’s Disease (1998–2021)
    Xiao-Wei Feng, Maryam Hadizadeh, Lin-Hong Zheng, Wei-Han Li · 2022 · Journal of Clinical Medicine
93. Aerobic exercise does not affect serum neurofilament light in patients with mild Alzheimer’s disease
    Kristian Steen Frederiksen, Camilla Steen Jensen, Peter Høgh et al. · 2023 · Frontiers in Neuroscience
94. Probiotics that Ameliorate Cognitive Impairment through Anti-Inflammation and Anti-Oxidation in Mice
    Shinhui Lee, Sanung Eom, Jiwon Lee, Minsu Pyeon, Kiyeop Kim, Kyu Yeong Choi, Junghee Lee, Da Jeong Shin, Kun Ho Lee, Sejong Oh et al. · 2023 · Food Science of Animal Resources
95. Advances in the treatment and management of frontotemporal dementia
    Alberto Benussi, Barbara Borroni · 2023 · Expert Review of Neurotherapeutics
96. The efficacy and safety of anti-Aβ agents for delaying cognitive decline in Alzheimer’s disease: a meta-analysis
    Jiaxuan Li, Xin Wu, Xin Tan, Shixin Wang, Ruisi Qu, Xiaofeng Wu, Zhouqing Chen, Zhong Wang, Gang Chen · 2023 · Frontiers in Aging Neuroscience
97. Cellular senescence: A novel therapeutic target for central nervous system diseases
    Shuang-Yin Lei, Yang Qu, Yu-Qian Yang, Jia‐Cheng Liu, Yi-Fei Zhang, Shengyu Zhou, Qianyan He, Hang Jin, Yi Yang, Zhen‐Ni Guo · 2024 · Biomedicine & Pharmacotherapy
98. SGLT-2 Inhibitors in the Prevention and Progression of Neurodegenerative Diseases: A Narrative Review
    Paulina Kostrzewska, Paweł Kuca, Przemysław Witek, Jolanta Małyszko, Natalia Madetko‐Alster, Piotr Alster · 2025 · Neurology and Therapy
99. Estimated Societal Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
    Amir Abbas Tahami Monfared, Weicheng Ye, Aditya Sardesai, Henri Folse, Ameya Chavan, Kang Kang, Quanwu Zhang · 2023 · Neurology and Therapy
100. Integrative multiomics reveals common endotypes across PSEN1, PSEN2, and APP mutations in familial Alzheimer’s disease
     Phoebe Valdes, Andrew B. Caldwell, Qing Liu, Michael Q. Fitzgerald, Srinivasan Ramachandran, Celeste M M. Karch, Dominantly Inherited Alzheimer Network (DIAN), Sarah Adams, Ricardo Allegri, Aki Araki et al. · 2025 · Alzheimer s Research & Therapy